News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Domestic business was up 41.9% YoY and 27.7% QoQ
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Subscribe To Our Newsletter & Stay Updated
